ConductScience.org, home

Paper20032971

CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis.

Stuhlmüller B and 9 others. Clin Pharmacol Ther, 2010. Cited by 67 papers, by iCite.

Cite this record

ConductScience Library. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis. Papers, record 20032971. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20032971

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis.
PubMed
Journal
Clin Pharmacol Ther
PubMed
Year
2010
PubMed
Publication types
Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
67
iCite
Relative citation ratio, by iCite
1.74
iCite
Revised in PubMed
2017-11-16
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Stuhlmüller BB
2Häupl TT
3Hernandez MMM M
4Grützkau AA
5Kuban RJR-J
6Tandon NN
7Voss JWJ W
8Salfeld JJ
9Kinne RWR W
10Burmester GRG R

Source PubMed

Download CSV of authors

Topics22

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Antirheumatic AgentsMajor topic
Arthritis, RheumatoidMajor topic
CD11c AntigenMajor topic
Transcription, GeneticMajor topic
Tumor Necrosis Factor-alphaMajor topic
Adalimumab
Adult
Aged
Antibodies, Monoclonal, Humanized
Biomarkers
Cohort Studies
Female
Genetic Markers
Humans
Male
Methotrexate
Middle Aged
Monocytes
Predictive Value of Tests
Protein Array Analysis
Treatment Outcome

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02878161Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World"Background

Source ClinicalTrials.gov

Download CSV of trials

Cited by45

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 67 citations.

PMIDTitleJournalYearIn PapersSource
42539492Spatial transcriptomic analysis of kidney biopsies identifies activation of complement and SPP1 networks in Staphylococcus infection-associated glomerulonephritis.Front Nephrol2026https://conductscience.org/library/papers/42539492PubMed
41916981CXCR3 is associated with T-cell-induced heart damage in acute rheumatic fever.Nat Commun2026https://conductscience.org/library/papers/41916981PubMed
40428231Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and Nrf2 Activation.Diagnostics (Basel)2025https://conductscience.org/library/papers/40428231PubMed
39346909Causal relationship, shared genes between rheumatoid arthritis and pulp and periapical disease: evidence from GWAS and transcriptome data.Front Immunol2024https://conductscience.org/library/papers/39346909PubMed
39058384miRNAs and NFKB1 and TRAF6 target genes: The initial functional study in CD14+ monocytes in rheumatoid arthritis patients.Genet Mol Biol2024https://conductscience.org/library/papers/39058384PubMed
38779469Towards Personalized Medicine in Rheumatoid Arthritis.Open Access Rheumatol2024https://conductscience.org/library/papers/38779469PubMed
38540800Molecular Profiling of Axial Spondyloarthritis Patients Reveals an Association between Innate and Adaptive Cell Populations and Therapeutic Response to Tumor Necrosis Factor Inhibitors.Biomolecules2024https://conductscience.org/library/papers/38540800PubMed
37509625DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis.Biomedicines2023https://conductscience.org/library/papers/37509625PubMed
36015273-Omic Approaches and Treatment Response in Rheumatoid Arthritis.Pharmaceutics2022https://conductscience.org/library/papers/36015273PubMed
36009355Gene Ontology Analysis Highlights Biological Processes Influencing Non-Response to Anti-TNF Therapy in Rheumatoid Arthritis.Biomedicines2022https://conductscience.org/library/papers/36009355PubMed
35003068Toward Overcoming Treatment Failure in Rheumatoid Arthritis.Front Immunol2021https://conductscience.org/library/papers/35003068PubMed
34148193A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study.Rheumatol Ther2021https://conductscience.org/library/papers/34148193PubMed
33397492Identification of differentially expressed genes, signaling pathways and immune infiltration in rheumatoid arthritis by integrated bioinformatics analysis.Hereditas2021https://conductscience.org/library/papers/33397492PubMed
32909363Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis.Arthritis Rheumatol2021https://conductscience.org/library/papers/32909363PubMed
32797404Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis.Rheumatol Ther2020https://conductscience.org/library/papers/32797404PubMed
31647025Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor.Arthritis Res Ther2019https://conductscience.org/library/papers/31647025PubMed
31227791Association of ITGAX and ITGAM gene polymorphisms with susceptibility to IgA nephropathy.J Hum Genet2019https://conductscience.org/library/papers/31227791PubMed
30941119Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses.Front Immunol2019https://conductscience.org/library/papers/30941119PubMed
30642076TNF-α Inhibitors Decrease Classical CD14hiCD16- Monocyte Subsets in Highly Active, Conventional Treatment Refractory Rheumatoid Arthritis and Ankylosing Spondylitis.Int J Mol Sci2019https://conductscience.org/library/papers/30642076PubMed
29520680[Relevance of big data for molecular diagnostics].Z Rheumatol2018https://conductscience.org/library/papers/29520680PubMed

See all 45 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ITGAX3687PubTator's text mininghttps://conductscience.org/library/genes/3687NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20032971

GET https://conductscience.org/api/papers/v1/20032971/cited_by?page=2